News
Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for its ...
Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...
If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks ...
Opinion
GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly LawsuitThis lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...
5d
Zacks Investment Research on MSNLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results